INHALED NITRIC OXIDE MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Inhaled Nitric Oxide Market, By Product Type (Inhaled Nitric Oxide Delivery Systems, Consumables, (Nitric Oxide Cylinders and Delivery Accessories), and Others), By Application (Neonatal Respiratory Treatment, Chronic Obstructive Pulmonary Disease (COPD), acute respiratory distress syndrome (ARDS), Tuberculosis Treatment, Malaria Treatment, and Others), By Strength (100 ppm, 800 ppm, and Others), By End User (Hospitals, Ambulatory Surgical Centers, and Home Care Settings), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

On August 6, 2024, Beyond Air, Inc. a commercial stage medical device and biopharmaceutical company, shared data from a study indicating that on high-dose inhaled nitric oxide (iNO) for COVID-19 viral pneumonia showed that intermittent 150-ppm iNO treatment is safe and effective in reducing oxygen support needs and improving recovery times. Patients treated with iNO required less oxygen, achieved better oxygen saturation, and showed a trend toward earlier discharge compared to those on standard care. No treatment-related adverse events were observed, underscoring the therapy's safety. These results highlight the potential of high-dose iNO in managing viral pneumonia, suggesting further study to explore its benefits across other respiratory illnesses.
In May 2023, Pieris Pharmaceuticals, Inc., a clinical-stage biotechnology company developing novel biotherapeutics through its proprietary Anticalin technology for respiratory disorders and cancer, announced the safety review of a 10 mg dry powder dose cohort from its recent multicenter, placebo-controlled phase 2a study.
In February 2023, Vero Biotech announced the U.S. FDA approval for its second-generation Genosyl device, designed to deliver inhaled nitric oxide for use with rebreathing anesthesia in operating room settings. Although the third-generation Genosyl device has also recently received FDA approval, it has not yet been validated for rebreathing anesthesia.